Ultrasound findings of fatty liver are very common in outpatient clinics and the common questions are: How did I get fatty liver? What medication can I use? As a brief introduction, fatty liver is divided into two categories: alcoholic fatty liver and non-alcoholic fatty liver. For the former, the cause is clearer and the treatment is, of course, to stop drinking. Primary NAFLD is mainly related to insulin resistance and genetic susceptibility, and can be attributed to metabolic syndrome, such as rapid weight gain and overweight due to overnutrition, fatty liver associated with metabolic syndrome such as obesity, diabetes, hyperlipidemia, and cryptogenic fatty liver. In contrast, secondary pulmonary trans-alcoholic fatty liver is caused by some specific causes, including malnutrition, total parenteral nutrition, rapid weight loss after bariatric surgery, and fatty liver due to drug/environmental and industrial toxicity poisoning. Most patients with fatty liver have no specific self-conscious discomfort, and some present with vague discomfort in the liver area, weakness, abdominal distention, and indigestion. So, what should I do if I have NAFLD? The first step is to develop a reasonable energy intake and diet structure adjustment, moderate aerobic exercise, correction of poor lifestyle and behavior, prevention of dramatic weight loss, drug abuse and other factors that may induce liver disease deterioration. Next is weight loss. All patients with overweight, visceral obesity, and non-alcoholic fatty liver disease with rapid weight gain in a short period of time need to control their weight and reduce their waist circumference through lifestyle changes. In combination with type 2 diabetes, impaired glucose tolerance, increased fasting glucose and visceral obesity, metformin and thiazolidinediones can be considered to improve insulin resistance and control blood glucose. Those with dyslipidemia who still show mixed hyperlipidemia or hyperlipidemia combined with more than 2 risk factors after more than 3-6 months of basic treatment and application of weight loss and hypoglycemic drugs need to consider the addition of lipid-lowering drugs such as fibrates, statins or probucol. About the medication: for non-alcoholic fatty liver disease with abnormal liver function, metabolic syndrome, ineffective after 3-6 months of basic treatment, as well as those with NASH confirmed by liver biopsy and chronic progressive course of the disease, adjuvant therapy with drugs for liver disease can be used to antioxidant, anti-inflammatory and anti-fibrotic, and polyphosphocholine, vitamin E can be reasonably selected according to the drug performance, disease activity and disease stage. The use of polyphosphocholine, vitamin E, silymarin, ursodeoxycholic acid and other related drugs is reasonable according to the performance of the drugs and the disease activity and stage. The majority of patients with non-alcoholic fatty liver disease have a good prognosis, with slow or even quiescent hepatic histological progression and a relatively good prognosis. Even if steatohepatitis and hepatic fibrosis have been complicated in some patients, the hepatic histological changes can be reversed if timely diagnosis and treatment is received, and death from fat embolism due to fat cyst rupture is rare. A small number of patients with steatohepatitis progress to cirrhosis, and once cirrhosis occurs, their prognosis is poor. In most patients with steatohepatitis, weight and blood glucose control, lipid reduction, and liver histologic reversal can sometimes be achieved with non-pharmacologic measures such as dietary modifications and moderate aerobic exercise.